Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idec and Coulter Face Off

Executive Summary

Two makers of new antibody therapies for cancer are engaged in a fierce battle that's all about positioning. Idec recently won FDA's approval for {Rituxan}, which Genentech is co-promoting in the US. But young Coulter is proclaiming its {Bexxar}, still two years from market, will surpass {Rituxan} to become the gold standard treatment for non-Hodgkin's lymphoma. Will the companies limit each other's opportunities?
Advertisement

Related Content

Genta's Clinical Quest

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV000864

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel